Drug Profile
Agalsidase alfa - Takeda
Alternative Names: Replagal; SMP 536; TAK-675; α-galactosidase ALatest Information Update: 01 Feb 2024
Price :
$50
*
At a glance
- Originator Shire
- Developer Endo International; Medison Pharma; Orphan Australia; Samaritan Pharmaceuticals; Sumitomo Pharma; Takeda
- Class Galactosidases; Isoenzymes
- Mechanism of Action Alpha-galactosidase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Fabry's disease
Most Recent Events
- 03 Jan 2024 Takeda completes a phase III trial in Fabry's diseases in China (IV, Infusion) (NCT04974749)
- 06 May 2022 Phase-III clinical trials in Fabry's disease (Treatment-naive, In children, In adolescents, In adults) in China (IV) (NCT04974749)
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma